Uveitis is inflammation inside the eye, affecting the uvea and sometimes nearby structures like the retina. It can be triggered by autoimmune disease, infection, or injury, or appear without a clear cause. Treatment typically starts with steroid eye drops or injections, with immune-suppressing drugs added for chronic or severe cases.
What's actually going on in research
Trials are testing biologic drugs that target specific immune pathways, including adalimumab already approved for some forms of uveitis and newer agents like IL-6 and IL-17 inhibitors. Researchers are also studying sustained-release implants that deliver medication inside the eye for months, controlled-release drug delivery systems, and treatments for complications like macular edema and retinal damage.
Biologic therapies
TNF inhibitors like adalimumab are FDA-approved for non-infectious uveitis, and trials are testing whether other biologics used in rheumatoid arthritis and psoriasis can control eye inflammation. These drugs may spare people from long-term steroid side effects.
Sustained-release implants
Implants placed inside the eye can release medication steadily for months or years, reducing the need for frequent injections. Several new implant designs are being tested for chronic uveitis.
Macular edema treatment
Swelling in the central retina is a common complication that threatens vision. Trials are testing anti-VEGF drugs and targeted steroids to control this swelling more effectively.
What to know before you search
Eligibility often depends on whether the uveitis is infectious or non-infectious, which part of the eye is affected, disease activity level, and response to prior treatments including steroids.
What types of trials are currently open
- Biologic trials — Testing immune-targeting drugs, usually given by injection or infusion, to control inflammation without long-term steroids.
- Implant trials — Testing devices placed inside the eye that release medication slowly, aiming to control inflammation for months with a single procedure.
- Macular edema trials — Testing treatments for swelling in the central retina, which can blur vision even when inflammation is controlled.
- Corticosteroid trials — Testing new steroid formulations or delivery methods that may work better or cause fewer side effects.
- Observational studies — Following people with uveitis over time to learn which treatments work best for different causes and patterns of inflammation.
Recently added Uveitis trials
Complete eye imaging scans to help detect childhood eye inflammation
Uveitis is an inflammation inside the eye. Although rare, it is an important auto-inflammatory eye condition that affect children and young people (CYP). If not identified and treated promptly, it can lead to permanent vision loss. Uveitis is estimated to affect around 4-5 in every 100,000 children, and up to 26% of those with childhood-onset disease may develop severe visual impairment. Because uveitis often causes no symptoms, even when it is advanced, it is sometimes described as a "silent blinding disease" Uveitis can occur on its own or together with other immune-related conditions. It is the most common non-joint (extra-articular) complication of Juvenile Idiopathic Arthritis (JIA), the most frequent childhood auto-inflammatory joint disorder, which affects about 5.6 per 100,000 children in the UK. National guidelines from the Royal Colleges recommend regular uveitis screening for all children and young people with JIA. This study aims to assess whether a high-resolution, non-irradiating eye imaging system can accurately detect inflammatory cells inside the eye objectively. The scan is non-invasive, non-contact, painless, and well tolerated by children. It can take 50,000 images per second, allowing the front of the eye to be captured in seconds. These images will be analysed using validated automated algorithms to identify and measure signals from inflammatory cells objectively, without influence of human factor. The qualitative and quantitative information may help predict disease activity and monitor treatment response. We aim to compare the imaging results with the current standard slit-lamp eye examination in 300 children and young people (600 eyes). Both the imaging operators and the senior clinical examiners will be not know what each other's findings. The primary aim is to determine how AS-OCT imaging system is in detecting uveitis in children and if the results is the same as the standard eye test. The measurement data will also support early-phase deep-learning development to create a cost-effective, automated tool for diagnosing, grading, and crucially monitoring uveitis over time, particularly during treatments that involve complex immunosuppressive medications.
Try a physical activity program designed for women with Behçet disease
metabolci syndrom is highly prevalent in behcet disorder females. usually physical activity is recommended to solve this problem
Find Uveitis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.